Partnership to utilise complementary technology platforms to produce a differentiated ADC product

30 Nov 2017

Vaccinex and Catalent Biologics to collaborate on ADC development.

Catalent Pharma Solutions and Vaccinex have announced an agreement to develop an antibody-drug conjugate (ADC) using Catalent’s proprietary SMARTag conjugation platform and GPEx cell line engineering technologies, and Vaccinex’s proprietary ActivMAb technology. The collaboration will focus on developing the ADC against an undisclosed cancer target.

Partnership to utilise complementary technology platforms to produce a differentiated ADC product
Catalent's state-of-the-art Madison facility,

Catalent and Vaccinex will evaluate the ADC in various preclinical models and move it into cell line and process development, utilizing Catalent’s proprietary GPEx technology and development and manufacturing capabilities at its state-of-the-art Madison, Wisconsin facility.

“Vaccinex is excited to partner with Catalent Biologics to develop this novel ADC for the treatment of cancer. We feel that by combining an ActivMAb antibody with Catalent’s SMARTag conjugation technology, we can generate a unique, differentiated molecule to treat cancers overexpressing this particular target,” commented Raymond E. Watkins, Senior Vice President and Chief Operating Officer of Vaccinex.

“We are delighted to partner with an innovative company like Vaccinex to develop a product that has the potential to deliver better outcomes for patients,” added Mike Riley, Vice President & General Manager of Catalent Biologics. “The opportunity to leverage these complementary technology platforms provides great promise to produce a differentiated ADC product.”

Catalent’s proprietary SMARTag site-specific protein-modification and linker technologies were developed to enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. The technology employs natural post-translational modifications found in human cells to create “chemical handles” at predetermined sites on protein molecules. These sites can then be stably chemically conjugated to many different payloads. The control afforded by the technology enables identification of superior drugs from libraries of differentially designed conjugates. The GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency. To date, eight GPEx-based antibody and protein products are approved and marketed, and over 45 therapeutic candidates are currently in the clinic across the world.

ActivMAb is Vaccinex’s antibody discovery and optimization platform. It combines the advantages of both viral panning and cell sorting to enable the efficient identification of high-affinity, fully human antibodies from antibody libraries expressed in mammalian cells. A fusion protein of immunoglobulin heavy chain with a vaccinia membrane protein (Ig-VMP) has been developed that enables efficient expression on the surface of vaccinia virus, an enveloped mammalian virus, as well as on the surface of the infected cell.

Read More

Related news

Compact serialization-ready manual workstation

Compact serialization-ready manual workstation

11 Aug 2018

A cost-effective and space-saving solution for serializing cartons and performing multi-level aggregation on cases and pallets.

Read more 
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
BASF receives award for its portfolio of natural cosmetic ingredients

BASF receives award for its portfolio of natural cosmetic ingredients

7 Aug 2018

Company recognised for its innovation and continual delivery of new natural ingredients.

Read more 
Extended distribution agreement enables customers to continuously improve their bioprocesses

Extended distribution agreement enables customers to continuously improve their bioprocesses

6 Aug 2018

Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

3 Aug 2018

The plant will be first-of-its-kind in the US.

Read more 
Croda invests in SiSaf’s novel bio-courier technology

Croda invests in SiSaf’s novel bio-courier technology

3 Aug 2018

ProSilic will give Croda’s customers access to the next generation of targeted and controlled drug delivery.

Read more 
Breast cancer device receives FDA approval

Breast cancer device receives FDA approval

3 Aug 2018

The first non-radioactive, dual-tracer for sentinel lymph node biopsy approved in the US.

Read more 
Building contingency plans for an ambiguous post-Brexit market

Building contingency plans for an ambiguous post-Brexit market

31 Jul 2018

One company's positive approach to Brexit preparations, despite the lack of definition.

Read more 
Cherwell publishes guide on environmental monitoring processes and validation

Cherwell publishes guide on environmental monitoring processes and validation

31 Jul 2018

Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.

Read more